Cryo-Cell International, Inc. (CCEL) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryo-Cell International, Inc. on May 22, 2025, covering events occurring on May 17, 2025. The company is incorporated in Delaware and trades on the NYSE American under the symbol CCEL.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material legal event rather than financial performance.
Material Changes
- Termination of Material Definitive Agreement: Cryo-Cell received notice from Duke University terminating the Patent and Technology License Agreement effective May 17, 2025.
- Reason for Termination: Duke claims Cryo-Cell breached the agreement. This follows Cryo-Cell's prior filing of a demand for arbitration against Duke, alleging fraudulent inducement and various breaches by Duke.
- Scope of Agreement: The terminated agreement granted Cryo-Cell exclusive rights to commercialize certain licensed products and processes for the treatment and management of human diseases.
Outlook, Risks, and Contingencies
The termination of the Duke License Agreement represents a significant contingency and risk to Cryo-Cell's operations, as it impacts the company's exclusive rights to specific patent technologies and regulatory data. The ongoing arbitration dispute regarding fraudulent inducement and breach of contract remains a material uncertainty.
Investor Verification Checklist
- Verify the specific terms of the arbitration demand filed by Cryo-Cell against Duke University.
- Assess the impact of losing the exclusive license on Cryo-Cell's product pipeline and commercial strategy.
- Review prior disclosures regarding the allegations of fraudulent inducement made by Cryo-Cell.
- Monitor for further legal developments or potential settlement discussions between the parties.